Companies › Saol Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 2; Immunology, Metabolic and endocrine, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SL1002 | – | Phase 3 | Osteoarthritis Knee Pain | Nov 2026 |
| Sodium Dichloroacetate Pyruvate dehydrogenase kinase inhibitor | PDK2, PDK3, PDK4, PDK1 | Phase 3 | Pyruvate Dehydrogenase Complex Deficiency; Glioblastoma Multiforme | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02616484 | Sodium Dichloroacetate | Phase 3 | Pyruvate Dehydrogenase Complex Deficiency | Metabolic and endocrine | Aug 2025 |
| NCT05120284 | Sodium Dichloroacetate | Phase 2 | Glioblastoma Multiforme | Oncology | Jul 2026 |
| NCT07226258 | SL1002 | Phase 3 | Osteoarthritis Knee Pain | Immunology | Nov 2026 |
Industrial Farmacéutica Cantabria Shandong New Time Pharmaceutical Tolmar Rakuten Medical mAbxience Research
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.